A multivariable model of BRAF^V600E and ultrasonographic features for predicting the risk of central lymph node metastasis in cN0 papillary thyroid microcarcinoma

References

• Vuong H, Altibi A, Duong U, Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf). 2017;87(5):411–417. doi:10.1111/cen.1341328666074
   PubMed Web of Science ®Google Scholar
• La VC, Malvezzi M, Bosetti C, et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer Suppl. 2015;136(9):2187.
   Google Scholar
• Zuo H, Tang W, Yasuoka H, et al. A review of 227 cases of small papillary thyroid carcinoma. Eur J Surg Oncol. 2007;33(3):370–375.17071044
   PubMed Web of Science ®Google Scholar
• Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg. 2006;132(6):650–654. doi:10.1001/archotol.132.6.65016785411
   PubMedGoogle Scholar
• Cooper D, Doherty G, Haugen B, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi:10.1089/thy.2009.011019860577
   PubMed Web of Science ®Google Scholar
• Agcaoglu O, Sengun B, Ozoran E, et al. Should we perform routine prophylactic central neck dissection in patients with thyroid papillary microcarcinoma? Ann Ital Chir. 2018;89(undefined):485–488.30665217
   PubMedGoogle Scholar
• Sun QH, Zhang L, Yang JB, et al. [Related factors analysis for lymph node metastasis in papillary thyroid carcinoma: a series of 2 073 patients]. Zhonghua Wai Ke Za Zhi. 2017;55(8):592–598. doi:10.3760/cma.j.issn.0529-5815.2017.08.00828789509
   PubMedGoogle Scholar
• Sun W, Lan X, Zhang H, et al. Risk factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. PLoS One. 2015;10(10):e0139021. doi:10.1371/journal.pone.013902126431346
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2014;33(1):42–50. doi:10.1200/JCO.2014.56.825325332244
   PubMed Web of Science ®Google Scholar
• Moon HJ, Kwak JY, Kim EK, et al. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology. Ann Surg Oncol. 2009;16(11):3125–3131. doi:10.1245/s10434-009-0644-919644722
   PubMed Web of Science ®Google Scholar
• Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology. 2009;253(3):854–860. doi:10.1148/radiol.253309047119710001
   PubMed Web of Science ®Google Scholar
• Zheng X, Wei S, Han Y, et al. Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases. Ann Surg Oncol. 2013;20(7):2266. doi:10.1245/s10434-012-2851-z23370668
   PubMed Web of Science ®Google Scholar
• Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab. 2007;92(6):2264–2271. doi:10.1210/jc.2006-161317374713
   PubMed Web of Science ®Google Scholar
• Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2010;63(5):588–593. doi:10.1111/j.1365-2265.2005.02389.x
   Google Scholar
• Yang Y, Chen C, Chen Z, et al. Prediction of central compartment lymph node metastasis in papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2014;81(2):282–288. doi:10.1111/cen.1241724483297
   PubMed Web of Science ®Google Scholar
• Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22(41):6455–6457. doi:10.1038/sj.onc.120673914508525
   PubMed Web of Science ®Google Scholar
• Xiang Y, Lin K, Dong S, Qiao LI, Qiuxiang HE, Zhang X. Prediction of central lymph node metastasis in 392 patients with cervical lymph node-negative papillary thyroid carcinoma in Eastern China. Oncol Lett. 2015;10(4):2559–2564. doi:10.3892/ol.2015.354426622889
   PubMed Web of Science ®Google Scholar
• Kai Q, Lin T, Shan J. Risk Factors for central compartment lymph nodemetastasis in papillary thyriod microcarcinoma. Med J Wuhan Univ. 2015;36(04):558–561. doi:10.14188/j.1671-8852.2015.04.014
   Google Scholar
• Zhou Y, Gao E, Zhang W, et al. Factors predictive of papillary thyroid micro-carcinoma with bilateral involvement and central lymph node metastasis: a retrospective study. World J Surg Oncol. 2012;10:67. doi:10.1186/1477-7819-10-19822540396
   PubMed Web of Science ®Google Scholar
• Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103(11):2269–2273. doi:10.1002/cncr.2105515856429
   PubMed Web of Science ®Google Scholar
• Rossi R, Trasforini G, Bertelli F, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab. 2006;91(6):2171–2178. doi:10.1210/jc.2005-237216478817
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Z, Liu Y, Gao W, Zheng C. Risk factors for nodal metastasis in cN0 papillary thyroid microcarcinoma. Asian Pac J Cancer Prev. 2015;16(8):3361–3363. doi:10.7314/apjcp.2015.16.8.336125921145
   PubMedGoogle Scholar
• Gao Y, Qu N, Zhang L, Chen JY, Ji QH. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma. Tumour Bio. 2015;37(6):7453–7459. doi:10.1007/s13277-015-4535-326678888
   PubMedGoogle Scholar
• Kim KE, Kim EK, Yoon JH, Han KH, Moon HJ, Kwak JY. Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features. World J Surg. 2013;37(2):385–391. doi:10.1007/s00268-012-1826-323073506
   PubMed Web of Science ®Google Scholar
• Loh KC, Greenspan FS, Dong F, Miller TR, Yeo PP. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 1999;84(2):458–463. doi:10.1210/jcem.84.2.544310022401
   PubMed Web of Science ®Google Scholar
• Choi SY, Park H, Kang MK, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol. 2013;11(undefined):291. doi:10.1186/1477-7819-11-29124228637
   PubMedGoogle Scholar
• Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008;93(2):611–618. doi:10.1210/jc.2007-171718000091
   PubMed Web of Science ®Google Scholar
• Park AY, Son EJ, Kim JA, et al. Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. PLoS One. 2014;9(10):e110868. doi:10.1371/journal.pone.011086825337709
   PubMed Web of Science ®Google Scholar
• Kim SK, Park I, Woo JW, et al. Predicting factors for bilaterality in papillary thyroid carcinoma with tumor size <4 cm. Thyroid. 2017;27:2.
   Web of Science ®Google Scholar
• Virk RK, Dyke ALV, Finkelstein A, et al. BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype|[ndash]|phenotype correlation. Mod Pathol. 2013;26(1):62. doi:10.1038/modpathol.2012.15222918165
   PubMed Web of Science ®Google Scholar
• Li M, Zhu XY, Lv J, et al. Risk factors for predicting centrallymph node metastasis in papillary thyroid microcarcinoma (CN0):a study of 273 resections. Eur Rev Med Pharmacol Sci. 2017;21(17):3801–3807.
   Google Scholar